parkinson-2017-keynote

4 / 8

Page 26
Notes:
conferenceseries.com
Volume 7, Issue 5 (Suppl) J Alzheimers Dis Parkinsonism, an open access journal
ISSN: 2161-0460 Parkinson 2017
September 25-26, 2017
September 25-26, 2017 Chicago, USA
3rd International Conference on
Parkinson’s disease and Movement Disorders
Novel pharmaceutical interventions to relieve L-DOPA induced dyskinesia in Parkinson’s disease
Parkinson’s disease (PD) is a neurodegenerative disease caused by the death of dopaminergic neurons in the basal ganglia.
The golden standard for the treatment of PD is the dopamine (DA) replacement therapy with L-DOPA. DA acts on DA
receptors which belong to the superfamily of G Protein coupled receptors (GPCRs). However chronic treatment with L-DOPA
results in super sensitivity of DA receptors and unwanted side effects commonly known as L-DOPA induced dyskinesia. Here
we screened different formulations of L-DOPA oral route delivery which could result in a slow, sustained and timely delivery
of L-DOPA along with repurposed GPCR receptor antagonists that can up regulate two of the G protein coupled receptor
kinases GRK3 and 6 in brain that are down regulated in experimental animal models of PD. Our in vitro data in striatal
neuronal culture in the presence of DA and GPCR receptor antagonists showed an upregulation of GRK3 and 6 after 24 hours
of treatment at lower doses of DA. The behavioral studies in unilateral PD mice with DOPA formulations showed oral delivery
of DOPA relieved the akinesia seen in Parkinson’s disease and at the same time had less dyskinetic effects as revealed by mouse
cylinder test and AIMS respectively. Together our behavioral and signaling data demonstrate that L-DOPA delivered orally in
a sustained release form along with the peripheral DOPA decarboxylase inhibitors carbidopa and benserazide could relieve the
dyskinetic effects due to L-DOPA therapy in Parkinson’s disease.
Biography
Jayakumar Rajadas is the Founding Director of Biomaterials and Advanced Drug Delivery Laboratory at Stanford University. He is also an Adjunct Professor at
UCSF School of Pharmacy, University of California. He is currently working on the molecular mechanism of neurodegenerative disorders involved in Alzheimer's
and Parkinson's diseases. His research has also been involved in transforming nano science ideas into biomaterials and drug delivery technologies. Before moving
to Stanford, he served as the Founding Chair Person of the bio-organic and neurochemistry division at one of India’s national laboratories. He is a recipient of
several awards including Young Scientist award in Chemistry for the year 1996 from the Government of India. He has also won the Best Scientist award from the
Tamil Nadu state Government India in the year 1999. He is co-recipient of nine SPARK transnational awards in Stanford University. He has published over 194
papers with numerous granted/disclosed patents.
Jayakumar Rajadas
Stanford University, USA
Jayakumar Rajadas, J Alzheimers Dis Parkinsonism 2017, 7:5 (Suppl)
DOI: 10.4172/2161-0460-C1-029